This article will be permanently flagged as inappropriate and made unaccessible to everyone. Are you certain this article is inappropriate? Excessive Violence Sexual Content Political / Social
Email Address:
Article Id: WHEBN0026476724 Reproduction Date:
Esreboxetine is a selective norepinephrine reuptake inhibitor which was under development by Pfizer for the treatment of neuropathic pain and fibromyalgia but failed to show significant benefit over currently available medications and was discontinued.[1][2][3][4] It is the (+)-(S,S)-enantiomer of reboxetine and is even more selective in comparison.[1][5]
However, recently it has been shown that esreboxetine could be effective in fibromyalgia patients.[6]
M: CNS
anat (n/s/m/p/4/e/b/d/c/a/f/l/g)/phys/devp
noco (m/d/e/h/v/s)/cong/tumr, sysi/epon, injr
proc, drug (N1A/2AB/C/3/4/7A/B/C/D)
* Note that many TCAs, TeCAs, antipsychotics, ergolines, and some piperazines like buspirone and trazodone all antagonize α1-adrenergic receptors as well, which contributes to their side effects such as orthostatic hypotension.
* Note that many atypical antipsychotics and azapirones like buspirone (via metabolite 1-PP) antagonize α2-adrenergic receptors as well.
* Note that MAO-B inhibitors also influence norepinephrine/epinephrine levels since they inhibit the breakdown of their precursor dopamine.
Methamphetamine, Amphetamine, Norepinephrine, Methylphenidate, L-dopa